S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

ACHL Achilles Therapeutics PLC

1.06

-0.01 (-0.93%)

Nov 22 2024 - Closed

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

08/17/2023

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

05/19/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Linda Moran, as a duly authorized representative of Piper Sandler & Co Corporate & Venture Services FA, as attorney-in-fact for Karl Stuart Peggs

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Achilles Therapeutics Charts.

Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Achilles Therapeutics Charts.

Achilles Therapeutics PLC News

Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
Tuesday 19 November 2024 (5 days ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 14 November 2024 (1 week ago) • Edgar (US Regulatory)

Achilles Therapeutics Reports Third Quarter 2024 Financial Results
Thursday 14 November 2024 (1 week ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 19 September 2024 (2 months ago) • Edgar (US Regulatory)

Achilles Therapeutics Announces Strategic Update
Thursday 19 September 2024 (2 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 14 August 2024 (3 months ago) • Edgar (US Regulatory)

Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates
Wednesday 14 August 2024 (3 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 5 August 2024 (4 months ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Friday 24 May 2024 (6 months ago) • Edgar (US Regulatory)

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
Wednesday 22 May 2024 (6 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Friday 17 May 2024 (6 months ago) • Edgar (US Regulatory)

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Friday 17 May 2024 (6 months ago) • GlobeNewswire Inc.

More Achilles Therapeutics PLC News Articles

Global Developments (PK)

Baron Capital Enterprise (CE)

Anavex Life Sciences

Northwest Biotherapeutics (QB)

Kraig Biocraft Laborator... (QB)

Bioelectronics (PK)

Rennova Health (CE)

Lightwave Logic

Elite Pharmaceuticals (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions